Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse af oral og langtidsvirkende injicerbar cabotegravir og rilpivirin hos virologisk undertrykte børn, der lever med HIV-1, to til under 12 år gamle

Fase I/II-undersøgelse af sikkerhed, tolerabilitet, acceptabilitet og farmakokinetik af oral og langtidsvirkende injicerbar cabotegravir og rilpivirin hos virologisk undertrykte børn, der lever med HIV-1, to til under 12 år gamle

The purpose of the study is to evaluate the pharmacokinetics (PK), safety, tolerability, and acceptability of a long-acting injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age

Studieoversigt

Detaljeret beskrivelse

This is a Phase I/II, multicenter, open-label, non-comparative study to evaluate the safety, tolerability, acceptability, and PK of oral CAB and oral RPV followed by long-acting injectable CAB (CAB LA) and long-acting injectable RPV (RPV LA) to propose the weight-band dosing in virologically suppressed children living with HIV-1 aged two to less than 12 years. The study will also assess the long-acting injectable regimen with and without an oral lead-in period in the same study population.

Following completion of the study, if it is not possible for participants to access injections of CAB LA and RPV LA from non-study sources all participants may enter a Study Safety Extension (SSE) period. During the SSE period ongoing safety information to monitor for toxicities will be collected.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

90

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Gaborone, Botswana
        • Site 12701, Gaborone CRS
      • Molepolole, Botswana
        • Site 12702, Molepolole CRS
      • Belo Horizonte, Brasilien, 30.130-100
        • Site 5073, School of Medicine, Federal University of Minas Gerais
      • Rio de Janeiro, Brasilien, 21941-912
        • CRS 5071, Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Site 5030, Emory University School of Medicine NICHD CRS
    • Tennessee
      • Memphis, Tennessee, Forenede Stater, 38105
        • Site 6501, St. Jude Children's Research Hospital CRS
      • Johannesburg, Sydafrika, 1862
        • CRS 8052, Soweto IMPAACT CRS
      • Johannesburg, Sydafrika, 2001
        • Site 8051, Wits RHI Shandukani Research Centre CRS
    • KwaZulu-Natal
      • Umlazi, KwaZulu-Natal, Sydafrika, 4066
        • Site 30300, Umlazi CRS
      • Chiang Mai, Thailand, 50200
        • CRS 31784, Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS
      • Chiang Rai, Thailand, 57000
        • Site 5116, Chiangrai Prachanukroh Hospital NICHD CRS
    • Bangkoknoi
      • Bangkok, Bangkoknoi, Thailand, 10700
        • Siriraj Hospital, Mahidol University NICHD CRS (Site #5115)

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

2 år til 11 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria, Step 1: Entry for Cohort 1, Cohort 2a, and Cohort 2b

  • Parent or legal guardian is willing and able to provide written permission for child's study participation and, when applicable per institutional review board/ethics committee (IRB/EC) policies and procedures, child is willing and able to provide written assent for study participation.

Note: All sites must follow all applicable IRB/EC policies and procedures; for US sites, this includes single IRB (sIRB) policies and procedures.

  • Age two years old to less than 12 years old at entry
  • Body weight ≥10 kg and <40 kg at entry
  • At entry, willing and able to comply with the study visit schedule and other study requirements, as determined by the site investigator or designee.
  • Confirmed HIV-1-infection based on documented testing of two samples collected from two separate blood collection tubes per Sample #1 and Sample #2 requirements. Test results may be obtained from medical records or from testing performed during the study screening period
  • Has been on a stable unchanged ART regimen consisting of two or more drugs from two or more antiretroviral drug classes for at least six consecutive months (defined as 180 consecutive days) prior to entry.
  • Has no prior history of switching ART regimens for reasons related to treatment failure based on parent/guardian report and/or available medical records.

Note: Participants undergoing dose modifications for growth or who have switched to a new formulation due to toxicity, tolerability, or changes in national treatment guidelines are considered eligible per this inclusion criterion. Treatment failure should be defined by local guidelines.

  • From a specimen collected less than six months (defined as within 179 days) prior to entry, has at least one of the following documented plasma HIV-1 RNA results:

    • <50 copies/mL, or
    • less than the lower limit of detection of the assay
  • From a specimen collected in the 6-18 months (defined as 180 to 545 days) prior to entry, has at least one of the following documented plasma HIV-1 RNA results:

    • <50 copies/mL, or
    • less than the lower limit of detection of the assay
  • At screening, a documented plasma HIV-1 RNA <50 copies/mL.

Note: HIV-1 RNA test results at screening cannot be used to satisfy previously listed inclusion criterion. If participant does not have a documented HIV-1 RNA test result at screening that satisfies previously listed criteria, they should be referred for standard of care testing and return at a later date for screening.

  • Has normal, Grade 1, or Grade 2 results for all the following laboratory tests at screening (i.e., within 28 days prior to entry) based on grading per the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events:

    • AST (<5.0 x ULN)
    • ALT (<5.0 x ULN)
    • Total bilirubin (<2.6 x ULN)
    • Lipase (<3 x ULN)
    • Estimated glomerular filtration rate (eGFR; ≥60 ml/min/1.73 m2)
    • Platelets (≥50,000 cells/mm3 or ≥50.00 x 109 cells/L)
    • Hemoglobin (≥8.5 g/dL or ≥5.25 mmol/L)
    • Neutrophils (≥600 cells/mm3)

Note: Laboratory tests may be repeated during the study screening period (i.e., within 28 days prior to entry), with the latest result used for eligibility determination. ALT and total bilirubin should also be assessed

  • Has no evidence of chronic hepatitis B infection based on hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), and hepatitis B surface antibody (HBsAb) testing at screening; any of the following three combinations of test results are acceptable for inclusion:

    • HBsAg negative, HBcAb negative, HBsAb negative
    • HBsAg negative, HBcAb negative, HBsAb positive
    • HBsAg negative, HBcAb positive, HBsAb positive
  • At screening, has a mean QTc interval (based upon a triplicate reading) less than or equal to 450 msec based on an electrocardiogram (ECG) automated machine readout or calculated using the Fridericia formula.

  • For female participants of childbearing potential, not pregnant based upon negative blood or urine pregnancy test at entry. Childbearing potential is defined as nine years of age or older and:

    • Having reached menarche or
    • Engaging in sexual activity (self-reported) that could lead to pregnancy
  • For female participants of childbearing potential who are engaging in sexual activity (self-reported) that could lead to pregnancy, at entry, currently using at least one allowable highly effective method of contraception and agrees to use at least one allowable highly effective method of contraception throughout study participation and for at least 30 days after last oral product use and 48 weeks after last injectable study product use.

Highly effective methods of contraception include:

  • Surgical sterilization (i.e., hysterectomy, bilateral oophorectomy, tubal ligation, or salpingectomy)
  • Contraceptive intrauterine device or intrauterine system
  • Subdermal contraceptive implant
  • Progestogen injections
  • Combined estrogen and progestogen oral contraceptive pills
  • Percutaneous contraceptive patch
  • Contraceptive vaginal ring

Inclusion Criteria, Step 2: Continuation for Cohort 1 and Cohort 2a to injection phase

All participants enrolled in Cohort 1 or Cohort 2a will be assessed for eligibility to progress from the oral lead-in phase (Step 1) to the injection phase (Step 2), primarily based on the safety assessments from the Step 1 Week 4a study visit. Clinical assessments conducted prior to administering the first injection at the Week 4b visit will also be used to confirm eligibility to receive the injectable study product.

All of the following criteria must be met in order for a participant enrolled in Cohort 1 or Cohort 2a to be included in Step 2

  • Currently enrolled as a participant in Step 1.

  • Has normal, Grade 1, or Grade 2 results from all of the following laboratory test results based upon specimens collected at the Week 4a study visit or from confirmatory repeat testing of Week 4a study visit laboratory tests:

    • AST (<5.0 x ULN)
    • ALT (<5.0 x ULN)
    • Lipase (< 3 x ULN)
    • Estimated glomerular filtration rate (eGFR; ≥60 ml/min/1.73 m2))
    • Platelets (≥50,000 cells/mm3 or ≥50.00 x 109 cells/L)
    • Hemoglobin (≥8.5 g/dL or ≥5.25 mmol/L)
    • CK (<10 x ULN)

Note: For a Grade 2 ALT test result from this visit, refer to protocol for required participant management.

  • For female participants of childbearing potential not pregnant based upon negative blood or urine pregnancy test at the Week 4b study visit.
  • Assessed by the IoR or designee as sufficiently adherent to study products in Step 1 to permit an adequate evaluation of safety and tolerability as part of the oral lead in phase prior to entry into the injection phase.

Inclusion Criteria for Parents/Caregivers

Parents/caregivers of participants will be considered for enrollment to complete quantitative behavioral surveys and/or qualitative in-depth interviews (IDIs), as indicated in the SoE. One parent/caregiver per participant should be enrolled to complete all behavioral assessments, including the IDI, when applicable. Informed consent for parent/caregiver enrollment should be obtained at the entry visit, after the child participant's eligibility has been confirmed, and may be completed at a later date, if necessary. However, parent/caregiver consent must occur prior to any study assessments being conducted. The enrolled caregiver may be the different than the parent or legal guardian who provided written permission for the child to participate. If, at any point the enrolled parent/caregiver for a given participant withdraws from the study or is unable to complete remaining study assessments for any reason, they may be replaced.

Caregivers must meet the following criteria to be eligible to enroll in IMPAACT 2036:

  • 18 years of age or older
  • Able and willing to provide written informed consent consistent with site IRB/EC policies and procedures
  • Caregiver, defined as a biological parent, legal guardian, or other person who provides significant emotional, psychological, and/or physical care to a child enrolled in IMPAACT 2036, based on self-report

Exclusion Criteria, Step 1: Entry for Cohort 1, Cohort 2a, and Cohort 2b

Potential participants must be excluded from the study if any of the conditions specified below are identified during the screening period (i.e., within 28 days prior to study entry). The screening period begins when parental permission and informed assent (if applicable) are obtained and ends immediately prior to enrollment. For criteria involving a potential participant's medical history, it is expected that each exclusionary condition will be assessed at screening and subsequently reviewed and confirmed on the day of study entry, prior to enrollment. In these criteria, "at entry" is used to refer to the day of enrollment in the study

  • Within 6 months prior to entry, any HIV-1 RNA value >400 copies/mL OR two consecutive "viral blips," defined as an HIV-1 RNA value ≥50 copies/mL but ≤400 copies/mL.
  • As determined by the IoR or designee, and based on available medical records, known or suspected resistance to NNRTIs.

Note: Prior receipt of NNRTIs for prophylaxis or treatment is not exclusionary

  • As determined by the IoR or designee, and based on available medical records, known or suspected resistance to INSTIs.

  • Ongoing congestive heart failure, symptomatic arrhythmia, or any current clinically significant cardiac disease, as determined by the IoR or designee, and based on available medical records.

  • Has any of the following, as determined by the IoR or designee based on participant/parent/guardian report and available medical records:

    • Current hepatitis C infection
    • Current clinically significant hepatic disease
    • Current or anticipated need for chronic anti-coagulation
    • History of known or suspected bleeding disorder, including a history of prolonged bleeding
    • History of sensitivity to heparin or heparin-induced thrombocytopenia, as determined by the IoR or designee, based on available medical records
    • Risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, hypomagnesemia)
    • Known or suspected allergy to study product components.
    • Known phobia to needles
  • More than one seizure within one year (defined as within 365 days) prior to entry, or unstable or poorly controlled seizure disorder, as determined by the IoR or designee, and based on available medical records.

  • Has the following combination of laboratory test results at screening (i.e., from specimens collected within 28 days prior to entry): ALT greater than or equal to 3 x ULN and total bilirubin greater than or equal to 1.5 x ULN and direct bilirubin greater than 35% of total bilirubin.

  • At entry, known active tuberculosis infection, as determined by the IoR or designee based on participant/parent/guardian report and available medical records.

  • At entry, any ongoing pancreatitis as determined by the IoR or designee based on participant/parent/guardian report and available medical records.

  • At entry, has symptoms suggestive of active coronavirus disease 2019 (COVID-19) or test results or contacts that require quarantine per local clinical practice, public health, and/or infection control guidelines as determined by the IoR or designee based on participant/parent/guardian report and available medical records.

Note: Potential participants with symptoms suggestive of active COVID-19, test results, and/or contacts that require quarantine may resume screening (or be re-screened) after symptoms have resolved and applicable quarantine requirements have been completed.

  • Receipt of any prohibited medication within 7 days prior to entry, with the exception of antiviral agents that are part of the participant's ART regimen, as determined by the site investigator based on participant/parent/guardian report and available medical records

Note: Medications and vaccines approved for emergency use (e.g., COVID vaccines) that do not appear in the IMPAACT 2036 Prohibited and Precautionary Medications listing are not exclusionary may be administered as per standard of care.

  • Any past or current exposure to CAB LA or RPV LA
  • At entry, based on physical examination, has a current inflammatory skin condition that compromises the safety of intramuscular injections, as determined by the IoR or designee.
  • At entry, based on physical examination, has a dermatological condition overlying the buttock or upper thigh region, which, in the IoR or designee's opinion, may interfere with the interpretation of injection site reactions.
  • Enrolled in another clinical trial of an investigational agent, device, or vaccine.
  • Has any documented or suspected clinically significant medical or psychiatric condition or any other condition or social circumstance that, in the opinion of the site investigator, would make participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Exclusion Criteria, Step 2: Continuation for Cohort 1 and Cohort 2a to injection phase

Participants in Cohort 1 or Cohort 2a who meet any of the following criteria will be excluded from Step 2:

  • Has permanently discontinued oral study product.
  • Occurrence of any grade 3 or higher adverse event assessed as related to study product during Step 1.
  • Any other condition or social circumstance situation that, in the opinion of the IoR or designee, would make continued study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Exclusion Criteria for Parents/Caregivers

  • Any condition or social circumstance situation that, in the opinion of the IoR or designee, would make study participation unsafe for the caregiver or the child study participant, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Cohort 1

Cohort 1 will receive Once daily oral CAB + oral RPV through the Week 4b visit, followed by intramuscular injection doses of CAB LA + RPV LA every four weeks (Q4W dosing regimen) or every eight weeks (Q8W dosing regimen)

Tablet

Injectable

Eksperimentel: Cohort 2A

Cohort 2A: Once daily doses of oral CAB + oral RPV through the Week 4b visit, followed by Q4W or Q8W intramuscular injection doses of CAB LA + RPV LA.

Tablet

Injectable

Eksperimentel: Cohort 2B

Cohort 2B: Q4W or Q8W intramuscular injection doses of CAB LA + RPV LA.

Injectable

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Koncentrationer før dosis (CO) (kohorte 1, tabletter)
Tidsramme: I uge 2
I uge 2
Uge 5 koncentrationer (C5WK) (kohorte 1, injektioner)
Tidsramme: Gennem uge 5
Gennem uge 5
Uge 12 koncentrationer (C12WK) (kohorte 1, injektioner)
Tidsramme: Til og med uge 12
Til og med uge 12
Laveste koncentrationer (Ct) før IM-doser til og med uge 24 (kohorte 1, injektioner)
Tidsramme: Til og med uge 24
Til og med uge 24
Akkumuleringsforhold i uge 24 og uge 8 (kohorte 1, injektioner)
Tidsramme: I uge 8 og 24
I uge 8 og 24
Andel af børn, der oplever en lægemiddelrelateret sikkerhedshændelse under CAB + RPV oral indledningsperiode (kohorte 1)
Tidsramme: Til og med uge 4a
Til og med uge 4a
Andel af børn, der oplever en grad 3 af højere uønskede hændelser i løbet af CAB + RPV oral indledningsperiode (kohorte 1)
Tidsramme: Til og med uge 4a
Til og med uge 4a
Andel af børn, der oplever en SAE under CAB + RPV oral indledningsperiode (kohorte 1)
Tidsramme: Til og med uge 4a
Til og med uge 4a
Andel af børn, der oplever for tidlig permanent seponering af undersøgelsesbehandling på grund af en uønsket hændelse i CAB + RPV oral indledningsperiode (kohorte 1)
Tidsramme: Til og med uge 4a
Til og med uge 4a
Andel af børn, der oplever en lægemiddelrelateret sikkerhedsfejl i løbet af de 24 uger med CAB + RPV (oral og injicerbar) (kohorte 1)
Tidsramme: Uge 4b ​​til og med uge 28
Uge 4b ​​til og med uge 28
Andel af børn, der oplever en grad 3 eller højere bivirkning i løbet af de 24 uger med CAB + RPV (oral og injicerbar) (Kohorte 1)
Tidsramme: Uge 4b ​​til og med uge 28
Uge 4b ​​til og med uge 28
Andel af børn, der oplever en SAE i løbet af de 24 uger med CAB + RPV (oral og injicerbar) (Kohorte 1)
Tidsramme: Uge 4b ​​til og med uge 28
Uge 4b ​​til og med uge 28
Andel af børn, der oplever for tidlig permanent afbrydelse af undersøgelsesbehandling på grund af en bivirkning i løbet af de 24 uger med CAB + RPV (oral og injicerbar) (kohorte 1)
Tidsramme: Uge 4b ​​til og med uge 28
Uge 4b ​​til og med uge 28
AUC (Cohort 1, tablets)
Tidsramme: At week 2

Area under the curve from start of dose to 8 hours post dose

At week 2
CL/F (Cohort 1, tablets)
Tidsramme: At week 2

apparent clearance from start of dose to 8 hours post dose

At week 2
Cmax (Cohort 1, tablets)
Tidsramme: At week 2

Peak concentration from start of dose to 8 hours post dose

At week 2
Tmax (Cohort 1, tablets)
Tidsramme: At week 2

Time of maximal concentration from start of dose to 8 hours post dose

At week 2

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Akkumuleringsforhold Wk 24:Wk 8 og Wk 48: Wk 8 (Kohorte 2a), Wk 20:Wk4 og Wk 44: Wk 4 (Kohorte 2b
Tidsramme: I uge 8, 48 og 72
I uge 8, 48 og 72
Ct før IM doser gennem ugen. 24 og uge. 48 (Kohorte 2a)
Tidsramme: Ved Uge. 24 og uge. 48
Ved Uge. 24 og uge. 48
Ct før IM doser gennem Ug. 20 og Ug. 44 (Kohorte 2b)
Tidsramme: I uge 20 og 44
I uge 20 og 44
Andel af børn, der oplever en lægemiddelrelateret sikkerhedsfejl gennem uge 48 og 72 af CAB + RPV (oral og injicerbar) (kohorte 1)
Tidsramme: Til og med uge 48 og 72
Til og med uge 48 og 72
Andel af børn, der oplever en grad 3 eller højere bivirkning gennem uge 48 og 72 af CAB + RPV (oral og injicerbar) (kohorte 1)
Tidsramme: Til og med uge 48 og 72
Til og med uge 48 og 72
Andel af børn, der oplever en SAE gennem uge 48 og 72 med CAB + RPV (oral og injicerbar) (kohorte 1)
Tidsramme: Til og med uge 48 og 72
Til og med uge 48 og 72
Andel af børn, der oplever for tidlig permanent afbrydelse af undersøgelsesbehandling på grund af en bivirkning gennem uge 48 og 72 med CAB + RPV (oral og injicerbar) (kohorte 1)
Tidsramme: Til og med uge 48 og 72
Til og med uge 48 og 72
Andel af børn, der har HIV-1 RNA
Tidsramme: I uge 24, 48 og 72
I uge 24, 48 og 72
Andel af børn, der har HIV-1 RNA
Tidsramme: I uge 24, 48 og 72
I uge 24, 48 og 72
Andel af børn med bekræftet virologisk svigt i uge 24, 48 og 72, mens de var på CAB + RPV (kohorte 1)
Tidsramme: I uge 24, 48 og 72
I uge 24, 48 og 72
Svar fra børn og/eller forældre/plejere på spørgeskemaer om CAB- eller RPV-bivirkninger, smerter forbundet med injektioner og reaktioner på injektionsstedet i uge 24, 48 og 72 (kohorte 1)
Tidsramme: I uge 24, 48 og 72
I uge 24, 48 og 72
Barn og/eller forældre/plejer rapporterede holdninger til CAB eller RPV, herunder villighed til at bruge i uge 24, 48 og 72 (kohorte 1)
Tidsramme: I uge 24, 48 og 72
I uge 24, 48 og 72
Median for CD4-antal og -procent i uge 24, 48 og 72 (kohorte 1)
Tidsramme: I uge 24, 48 og 72
I uge 24, 48 og 72
Medianændring fra baseline CD4-antal og procent i uge 24, 48 og 72 (kohorte 1)
Tidsramme: I uge 24, 48 og 72
I uge 24, 48 og 72
Barn og/eller forældre/plejer rapporterede holdninger til CAB (kohorte 2) eller RPV, herunder villighed til at bruge for børn, der er på 48 uger med CAB + RPV (oral og injicerbar) ELLER 44 uger med CAB LA + RPV LA (injicerbar)
Tidsramme: I uge 44 og 48
I uge 44 og 48
Andel af børn, der oplever en lægemiddelrelateret sikkerhedsfejl i løbet af de 48 uger med CAB + RPV (oral og injicerbar) ELLER de 44 uger med CAB LA + RPV LA (injicerbar) (kohorte 2)
Tidsramme: I uge 44 og 48
I uge 44 og 48
Andel af børn, der oplever en grad 3 eller højere bivirkning i løbet af de 48 uger med CAB + RPV (oral og injicerbar) ELLER de 44 uger med CAB LA + RPV LA (injicerbar) (kohorte 2)
Tidsramme: I uge 44 og 48
I uge 44 og 48
Andel af børn, der oplever en SAE i løbet af de 48 uger med CAB + RPV (oral og injicerbar) ELLER de 44 uger med CAB LA + RPV LA (injicerbar) (Kohorte 2)
Tidsramme: I uge 44 og 48
I uge 44 og 48
Andel af børn, der oplever for tidlig permanent afbrydelse af undersøgelsesbehandling på grund af en bivirkning i løbet af de 48 uger med CAB + RPV (oral og injicerbar) ELLER de 44 uger med CAB LA + RPV (kohorte 2) LA (injicerbar)
Tidsramme: I uge 44 og 48
I uge 44 og 48
Andel af børn, der har HIV-1 RNA
Tidsramme: I uge 44 og 48
I uge 44 og 48
Andel af børn, der har HIV-1 RNA
Tidsramme: I uge 44 og 48
I uge 44 og 48
Andel af børn med bekræftet virologisk svigt under behandling for børn, der er på 48 uger med CAB + RPV (oral og injicerbar) ELLER 44 uger med CAB LA + RPV LA (injicerbar) (kohorte 2)
Tidsramme: I uge 44 og 48
I uge 44 og 48
Median- og interkvartilområde for CD4-tal og procentdel for børn, der er på 48 uger med CAB + RPV (oral og injicerbar) ELLER 44 uger med CAB LA + RPV LA (injicerbar) (kohorte 2)
Tidsramme: I uge 44 og 48
I uge 44 og 48
Ændring i median- og interkvartilintervallet fra baseline CD4-antal og procentdel for børn, der er på 48 uger med CAB + RPV (oral og injicerbar) ELLER 44 uger med CAB LA + RPV LA (injicerbar) (Kohorte 2)
Tidsramme: I uge 44 og 48
I uge 44 og 48
LA-dosering: Ct før IM-doser ved Ug. 48 og Wk. 72 og akkumuleringsforhold (Wk. 48:Wk. 8 og Wk. 72:Wk. 8) (Kohorte 1)
Tidsramme: I uge 8 og 48
I uge 8 og 48
Andel af deltagere, der havde genotypisk og fænotypisk resistens over for CAB eller RPV blandt børn, der oplever virologisk svigt, mens de var på CAB + RPV (kohorte 1)
Tidsramme: Til og med uge 72
Til og med uge 72
Andel af deltagere, der havde genotypisk og fænotypisk resistens over for CAB og RPV blandt børn, der oplever virologisk svigt, mens de var på 48 uger med CAB + RPV (oral og injicerbar) ELLER mens de var på 44 uger med CAB LA + RPV LA (injicerbar) (kohorte 2)
Tidsramme: I uge 44 og 48
I uge 44 og 48
Child and/or parent/caregiver response to questionnaires (Cohort 2)
Tidsramme: at week 44 and 48

about CAB or RPV side effects, pain associated with injections and injection site reactions for children who are on 48 weeks of CAB+RPV(oral and injectable) OR 44 weeks of CAB LA+RPV LA (injectable)

at week 44 and 48

Andre resultatmål

Resultatmål
Tidsramme
CAB- og RPV-koncentrationer 8 til 48 uger efter den endelige im-dosis
Tidsramme: I uge 8 og 48
I uge 8 og 48
Andel af børn, der oplever en lægemiddelrelateret sikkerhedssvigt gennem 48 uger efter permanent seponering af CAB LA + RPV LA
Tidsramme: Til og med uge 48
Til og med uge 48
Andel af børn, der oplever en grad 3 eller højere bivirkning gennem 48 uger efter permanent seponering af CAB LA + RPV LA
Tidsramme: Til og med uge 48
Til og med uge 48
Andel af børn, der oplever en SAE gennem 48 uger efter permanent seponering af CAB LA + RPV LA
Tidsramme: Til og med uge 48
Til og med uge 48
PO-dosering: Ug. 2 AUC, CL/F, Cmax, Tmax og præ-dosis koncentrationer (C0) efter administrationsmåde
Tidsramme: I uge 2
I uge 2

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

24. januar 2024

Primær færdiggørelse (Faktiske)

27. oktober 2026

Studieafslutning (Anslået)

31. marts 2029

Datoer for studieregistrering

Først indsendt

13. december 2022

Først indsendt, der opfyldte QC-kriterier

13. december 2022

Først opslået (Faktiske)

21. december 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • IMPAACT 2036
  • DAIDS Study ID (Anden identifikator: 38932)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Individual participant data that underlie results in the publication, after deidentification.

IPD-delingstidsramme

Beginning 3 months following publication and available throughout period of funding of the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Network by NIH.

IPD-delingsadgangskriterier

With whom?

  • Researchers who provide a methodologically sound proposal for use of the data that is approved by the IMPAACT Network.
  • For what types of analyses?
  • To achieve aims in the proposal approved by the IMPAACT Network.
  • By what mechanism will data be made available?
  • Researchers may submit a request for access to data using the IMPAACT "Data Request" form at: https:// www.impaactnetwork.org/ resources/study-proposals.htm. Researchers of approved proposals will need to sign an IMPAACT Data Use Agreement before receiving the data.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner